Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (il4r) antibody
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsAna Kostic, Ludmila Kelly, Xia Liu, Brendan J. Classon, Allen Radin
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) inhibitor such as an anti-IL-4Rα antibody.
Claims6
1-62. (canceled)
A method of treating a subject with eosinophilic esophagitis (EoE), the method comprising subcutaneously administering to the subject an anti-IL-4R antibody, wherein the anti-IL-4R antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:13 and a light chain comprising the amino acid sequence of SEQ ID NO:14,
- wherein the anti-IL-4R antibody is administered to the subject at a dose of 300 mg, and
- wherein prior to the treatment, the subject had ≥15 eosinophils per high power field (“eos/hpf”) in the esophagus.
Dependencies are inferred from the claim text.